TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: 911 use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Attempting to quit smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in clinical symptoms of peripheral neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory conduction velocity (SCV) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Kansas City Cardiomyopathy Questionnaire score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reactive Hyperemia Index (RHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of death at 90 days
Endpoint domain: Mortality/survival
Primary endpoint: Duration of MJS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of MJS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neck pain and disability scale (NPDS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neck sensitivity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain levels with neck movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: H. pylori density in the corpus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: inflammation and gastritis activity in the antrum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: inflammation and gastritis activity in the corpus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Concentration of hyaluronic acid and syndecan‐1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ANP secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Markers of kidney and liver function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rotation angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gibbosity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical summary measure score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Psychosocial summary measure score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality of life (QOL) of caregivers
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Levels of serum CRP, TNF-alpha, and IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean time for diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discrimination in health services
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in diurnal salivary cortisol rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Total leukocyte, neutrophil and lymphocyte counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: functional status at hospital discharge
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Comprehension levels
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: total respiratory impedance Zrs5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: total airway resistance Rrs5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: central airway resistance Rrs20
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Urinary podocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction in sevoflurane minimum alveolar concentration (MAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative resting pain at 1 hour and POD 1-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resumption of daily activities by 48 hours
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Fall incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative haemorrhage and blood transfusion requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean whole body TcPO(2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower extremity TcPO(2) levels below 30 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate and extent of bioavailability (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: role limitation score
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: mean total blemish count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: HAM-A total score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: letter classification accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symbol rate of a BCI typing system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum white blood cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Withdrawal due to manic symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of treatment for allergic conjunctivitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MMR at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free survival at 3 years
Endpoint domain: Mortality/survival
Primary endpoint: incidence of blocked lines requiring alteplase or urokinase infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for surgical replacements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Early onset of response (PASI50 at Week 4 or 8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of successful respiratory gating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality or readmission
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of exclusive breastfeeding at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: median increase in tumor size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: subjective response to alcohol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADC value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GLx/Cr
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: full-scale IQ of NPT
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Nasal chloride transport response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of nasal epithelial cells expressing apical full-length CFTR protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mycological cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Relapse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Occurrence of severe and life-threatening treatment-related complications
Endpoint domain: Adverse events/effects
Primary endpoint: Mean absolute difference between planned and achieved tibial implant positions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: death/stroke/myocardial infarction event-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: major adverse cardiac and cerebrovascular event (MACCE) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cumulative incidence of definite stent thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: Walking limitation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Walking recovery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Serum alkaline phosphatase level changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intrarater reliability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative release of CK-MB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Differential gene expression in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: median time to reach peak sensory block level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in hemostatic variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Self-reported anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parent-reported anxiety problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improve contraceptive practices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduce sexual IPV
Endpoint domain: Adverse events/effects
Primary endpoint: No episodes of metabolic decompensation
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in ammonia and glutamine plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: call impact
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Death or increase in left ventricular mass
Endpoint domain: Mortality/survival
Primary endpoint: Death or decrease in physical-health composite score
Endpoint domain: Mortality/survival
Primary endpoint: Need for additional uterotonic agents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: absolute humidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean difference in coronary diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stent dysfunction rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median cumulative survival
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of patients initiating new opioid medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Retention test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discomfort after embolization
Endpoint domain: Adverse events/effects
Primary endpoint: Pain reactions (grade 2 to 4)
Endpoint domain: Adverse events/effects
Primary endpoint: Peripheral blood cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Urinalysis data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of glandular atrophy and intestinal metaplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Level of serum gastrin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Oxygenation index improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: HIV‐1 DTH response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: p24-antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Food preoccupation reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healthy Eating Index‐2010 scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bowel preparation success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Tolerance of bowel preparation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adherence to preparation instructions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of local skin infection
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in apnea hypopnea index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement in arterial oxygen saturation nadir
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Subjective improvement in daytime sleepiness
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Bladder outlet obstruction (BOO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Urinary outcomes
Primary endpoint: Free maximum flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Detrusor pressure at maximum flow (P(det)Q(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Progression of arterial calcifications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bone resorption markers excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: hyperarousal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sleep difficulties
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: generativity scores
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: ego-integrity scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean reduction in HbA1-c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean reduction in FPG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in 2 hour OGTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: MCHS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PPA fall risk scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine betaine excretions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery of hepatic functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Serum osteocalcin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine free deoxypyridinoline levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV1 AUC*0‐1 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Expression of galectin-3 as a marker of thyroid malignancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Loss of eyelash reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum creatinine (Scre) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percent saturated fat intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean peak oxygen uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Glycated hemoglobin (A1C) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 3-point drop in MMSE
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: average duration until deterioration
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: umbilical cord magnesium levels at delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year Distant Metastasis-Free Survival (DMFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: IL-6 levels after exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IL-10 levels after exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IL-6/IL-10 ratio after exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Significant analgesic effect compared to placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse drug reactions experienced
Endpoint domain: Adverse events/effects
Primary endpoint: Cough resolution or improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cough-specific quality of life improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Degree of improvement in Hamilton Rating Scale for Depression scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of ECT treatments received
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: decrease in brush-border amino acid and glucose transport activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nesfatin-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asynchrony incidence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Relief of chest pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: overall incidence of nocturnal micturitions
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: incidence of insomnia
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: incidence of urgency
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: incidence of incontinence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: bothersome events due to intravesical therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: physics-related self-concept of ability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: discharge timing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Physical well-being
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Delayed ischemic neurologic deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neuropsychological function impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in prostate cancer incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Level of alanine amino-transferase (ALT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Clinical outcomes assessed using visual analog scale, Oswestry Disability Index, and Japanese Orthopedic Association scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital re-admissions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Average time to first analgesic requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean pulmonary artery pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: PTSD symptom reductions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-operative RBC demand
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in LDL cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post-training knowledge scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-training skill scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct answers to questions regarding package inserts
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Perceived physical function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: ZDS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: M-FIM score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FMS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean plasma urea level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean 24-hour creatinine clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Larger extent of myocardium at risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Larger infarct size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: motivation for substance use treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: FDG-PET SUVmax reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes